Abstract
Introduction
QVA149 is a once-daily dual bronchodilator combining the long-acting β2-agonist indacaterol and long-acting muscarinic antagonist glycopyrronium in development for the treatment of COPD. Here we report the cardio- and cerebro-vascular (CCV) safety profile of QVA149.
Methods
This was a pooled analysis of 3153 patients with moderate-to-severe COPD from four QVA149 Phase III studies.
Results
CCV adverse events (AEs) and serious AEs occurring in ≥2 patients and major adverse cardiovascular events (MACE) in all treatment groups are summarized in the table.
Conclusion
The CCV safety profile of QVA149 and placebo were similar with no evidence of increased risk of CCV events with QVA149 versus all comparators in patients with moderate-to-severe COPD.
- © 2013 ERS